loading
Oramed Pharmaceuticals Inc stock is traded at $2.12, with a volume of 62,017. It is up +0.00% in the last 24 hours and down -0.47% over the past month. Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.12
Open:
$2.13
24h Volume:
62,017
Relative Volume:
0.96
Market Cap:
$86.59M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
19.27
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-0.47%
1M Performance:
-0.47%
6M Performance:
-7.83%
1Y Performance:
-16.86%
1-Day Range:
Value
$2.11
$2.17
1-Week Range:
Value
$2.09
$2.17
52-Week Range:
Value
$1.82
$3.09

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name
Name
Oramed Pharmaceuticals Inc
Name
Phone
646-844-1164
Name
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Name
Employee
13
Name
Twitter
@OramedPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ORMP's Discussions on Twitter

Compare ORMP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ORMP
Oramed Pharmaceuticals Inc
2.12 87.01M 2.70M 5.53M -10.55M 0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-12-23 Downgrade Canaccord Genuity Buy → Hold
Feb-18-22 Initiated Cantor Fitzgerald Overweight
Apr-20-21 Initiated Canaccord Genuity Buy
Feb-09-21 Initiated National Securities Buy
Dec-03-20 Initiated Alliance Global Partners Buy
Mar-11-20 Initiated Aegis Capital Buy
Sep-11-19 Initiated Ladenburg Thalmann Buy
Dec-11-17 Resumed B. Riley FBR, Inc. Buy
May-26-16 Reiterated FBR Capital Outperform
Dec-01-15 Reiterated H.C. Wainwright Buy
Nov-19-15 Initiated FBR Capital Outperform
Apr-13-15 Resumed MLV & Co Buy
Jan-30-14 Reiterated Aegis Capital Buy
Jan-08-14 Reiterated Aegis Capital Buy
Jan-08-14 Initiated MLV & Co Buy
Dec-03-13 Initiated Aegis Capital Buy
View All

Oramed Pharmaceuticals Inc Stock (ORMP) Latest News

pulisher
01:58 AM

What analysts say about Oramed Pharmaceuticals Inc. stockRapid profit acceleration - jammulinksnews.com

01:58 AM
pulisher
Jul 21, 2025

Oral Proteins & Peptides Market to Surge to US$24 Billion by 2030, Driven by Chronic Disease Burden and Drug Delivery Innovation - Barchart.com

Jul 21, 2025
pulisher
Jul 20, 2025

Is Oramed Pharmaceuticals Inc. a good long term investmentPowerful market insights - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Oramed Pharmaceuticals Inc. stock priceRapid capital growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Oramed Pharmaceuticals Inc. Stock Analysis and ForecastUnprecedented profit potential - Autocar Professional

Jul 19, 2025
pulisher
Jul 15, 2025

What makes Oramed Pharmaceuticals Inc. stock price move sharplyFree Group Entry - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Oramed Pharmaceuticals Inc. stock attracts strong analyst attentionRisk Managed Trading Strategy - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Oramed Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Head to Head Survey: Oramed Pharmaceuticals (NASDAQ:ORMP) and Smith & Nephew SNATS (NYSE:SNN) - Defense World

Jul 10, 2025
pulisher
Jun 23, 2025

Alpha Tau Medical's $36.9M Financing: A Strategic Leap Toward Revolutionary Cancer Therapy - AInvest

Jun 23, 2025
pulisher
Jun 12, 2025

Oramed Pharmaceuticals : Announces Xiaoming Gao Joins Board of Directors - marketscreener.com

Jun 12, 2025
pulisher
Jun 04, 2025

Oral Biologics Market Outlook 2025: Rising Demand, Market Size, - openPR.com

Jun 04, 2025
pulisher
Jun 04, 2025

Two Sigma Advisers LP Invests $662,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World

Jun 04, 2025
pulisher
May 28, 2025

Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com

May 28, 2025
pulisher
May 28, 2025

Oral Biologics Market in 2025-2032 Detailed Study Analysis with - openPR.com

May 28, 2025
pulisher
May 28, 2025

Alpha Tau to Present at Jefferies Global Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Acusphere (OTCMKTS:ACUS) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World

May 28, 2025
pulisher
May 27, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average – Should You Sell? - Defense World

May 27, 2025
pulisher
May 21, 2025

Oramed Pharm Extends Stock Buyback Program - TipRanks

May 21, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World

May 18, 2025
pulisher
May 17, 2025

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World

May 17, 2025
pulisher
May 15, 2025

Oramed: Q1 Earnings Snapshot - New Haven Register

May 15, 2025
pulisher
May 13, 2025

Alpha Tau Medical appoints new board member By Investing.com - Investing.com India

May 13, 2025
pulisher
May 12, 2025

Alpha Tau Medical appoints new board member - Investing.com

May 12, 2025
pulisher
May 12, 2025

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire

May 12, 2025
pulisher
May 09, 2025

StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell - Defense World

May 09, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Trims Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World

May 05, 2025
pulisher
May 02, 2025

LPL Financial LLC Sells 21,250 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World

May 02, 2025
pulisher
Apr 29, 2025

Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize

Apr 29, 2025
pulisher
Apr 29, 2025

Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 28, 2025

Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq

Apr 28, 2025

Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
Cap:     |  Volume (24h):